Evommune (EVMN) Net Income Growth (1y) (2025 - 2026)

Evommune (EVMN) Net Income Growth (1y) (2025 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 66,741.39 Bn 66,741.11 Bn - -0.46%
2 Nanobiotix 1,912.31 Bn 1,912.25 Bn - -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn - -
4 BeOne Medicines 467.15 Bn 462.36 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 123.00 Bn 115.76 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 70.22 Bn 61.47 Bn 3.31 Bn -10.08%
7 Belite Bio 62.93 Bn 62.93 Bn - -
8 Argenx Se 55.76 Bn 50.57 Bn 1.41 Bn 63.48%
9 Alnylam Pharmaceuticals 37.70 Bn 34.69 Bn 959.66 Mn 1,228.66%
10 Evommune 384.18 Mn 172.71 Mn - -677.38%

Historic Data

Download Data
DateValue
Mar 31, 2026 -677.38%
Dec 31, 2025 -38.27%
Sep 30, 2025 -21.73%